Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | GCK | P35557 | 1/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045375 | 0.87 | GRM5 (0.76) | GRM5NPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL3362301 | 0.84 | CHRNB2 (0.64) | ALDH1A1GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16431044 | 0.84 | GRM5 (0.59) | ALDH1A1GRM5NPC1RAB9AGCK | |
| SCHEMBL4495742 | 0.81 | GRM5 (0.59) | GRM5NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL14097068 | 0.80 | LCK (0.66) | ALDH1A1GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10090736 | 0.79 | KMT2A (0.70) | ALDH1A1GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8660822 | 0.77 | CHRNB2 (0.63) | ALDH1A1GRM5NPC1RAB9AKCNK3 | |
| SCHEMBL10808813 | 0.76 | SMN1; SMN2 (0.60) | ALDH1A1GRM5NPC1RAB9AKCNK3 | |
| SCHEMBL12549321 | 0.76 | LCK (0.60) | ALDH1A1GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL821848 | 0.76 | MEN1 (0.68) | GRM5NPC1RAB9AKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113150463-B | Polymer composite shape-stabilized phase change material and preparation method thereof | 华南理工大学 | 2022-12-16 | — | — | CN | claimed |
| CN-110846130-B | Removal of unwanted components from oil compositions | 巴斯夫股份公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-115463681-B | Pd-La (OH) loaded on carbon material3Nanometer catalyst and preparation method and application thereof | 江西师范大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-116589738-A | High-filling waste printed circuit board nonmetal powder polymer composite material with phase change characteristic and preparation method thereof | 华南理工大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-113150463-B | Polymer composite shape-stabilized phase change material and preparation method thereof | 华南理工大学 | 2022-12-16 | — | — | CN | disclosed |
| CN-115463681-A | Carbon material loaded Pd-La (OH) 3 Nano catalyst and preparation method and application thereof | 江西师范大学 | 2022-12-13 | — | — | CN | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | ALDH1A1 2240/4885GRM5 1731/4885NPC1 2020/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | ALDH1A1 785/4885GRM5 4448/4885NPC1 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.